JP2018522571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522571A5 JP2018522571A5 JP2018506513A JP2018506513A JP2018522571A5 JP 2018522571 A5 JP2018522571 A5 JP 2018522571A5 JP 2018506513 A JP2018506513 A JP 2018506513A JP 2018506513 A JP2018506513 A JP 2018506513A JP 2018522571 A5 JP2018522571 A5 JP 2018522571A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cells
- cancer
- domain
- hexameric protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562204212P | 2015-08-12 | 2015-08-12 | |
| US62/204,212 | 2015-08-12 | ||
| US201662350447P | 2016-06-15 | 2016-06-15 | |
| US62/350,447 | 2016-06-15 | ||
| PCT/EP2016/069175 WO2017025610A1 (en) | 2015-08-12 | 2016-08-11 | Gitrl fusion proteins and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522571A JP2018522571A (ja) | 2018-08-16 |
| JP2018522571A5 true JP2018522571A5 (enExample) | 2019-09-12 |
Family
ID=56740217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506513A Pending JP2018522571A (ja) | 2015-08-12 | 2016-08-11 | Ｇｉｔｒｌ融合タンパク質およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10428131B2 (enExample) |
| EP (1) | EP3334758A1 (enExample) |
| JP (1) | JP2018522571A (enExample) |
| KR (1) | KR20180033588A (enExample) |
| CN (1) | CN108026158A (enExample) |
| AU (1) | AU2016306625A1 (enExample) |
| BR (1) | BR112018002039A2 (enExample) |
| CA (1) | CA2994346A1 (enExample) |
| CL (1) | CL2018000358A1 (enExample) |
| CO (1) | CO2018002450A2 (enExample) |
| HK (2) | HK1250044A1 (enExample) |
| IL (1) | IL257113A (enExample) |
| MX (1) | MX2018001787A (enExample) |
| RU (1) | RU2018108236A (enExample) |
| TW (1) | TW201718632A (enExample) |
| WO (1) | WO2017025610A1 (enExample) |
| ZA (1) | ZA201801640B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015095423A2 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| KR20160146747A (ko) | 2014-03-31 | 2016-12-21 | 제넨테크, 인크. | 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법 |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| US10526413B2 (en) | 2015-10-02 | 2020-01-07 | Hoffmann-La Roche Inc. | Bispecific antibodies specific for OX40 |
| WO2018027204A1 (en) | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| WO2018178074A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Trimeric antigen binding molecules specific for a costimulatory tnf receptor |
| WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| CN110869392A (zh) | 2017-05-16 | 2020-03-06 | 百时美施贵宝公司 | 用抗gitr激动性抗体治疗癌症 |
| US11919939B2 (en) * | 2017-05-23 | 2024-03-05 | Université De Genève | Beta-2-glycoprotein 1 derived peptide and use thereof for treating antiphospholipid syndrome |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| MY204117A (en) | 2017-06-22 | 2024-08-08 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| CA3061874A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| CA3066747A1 (en) | 2017-06-27 | 2019-01-03 | Novartis Ag | Dosage regimens for anti-tim-3 antibodies and uses thereof |
| JP2020527572A (ja) | 2017-07-20 | 2020-09-10 | ノバルティス アーゲー | 抗ｌａｇ−３抗体の投薬量レジメンおよびその使用 |
| WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
| CN111655288A (zh) | 2017-11-16 | 2020-09-11 | 诺华股份有限公司 | 组合疗法 |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| TWI869346B (zh) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| JP2021531306A (ja) | 2018-07-25 | 2021-11-18 | アドバンスド アクセラレーター アプリケーションズ エスエー | 神経内分泌腫瘍の処置の方法 |
| WO2020036867A1 (en) * | 2018-08-13 | 2020-02-20 | Inhibrx, Inc. | Ox40-binding polypeptides and uses thereof |
| US20230053449A1 (en) | 2018-10-31 | 2023-02-23 | Novartis Ag | Dc-sign antibody drug conjugates |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| JP2022514087A (ja) | 2018-12-21 | 2022-02-09 | ノバルティス アーゲー | ＩＬ－１β結合抗体の使用 |
| WO2020128637A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 binding antibodies in the treatment of a msi-h cancer |
| US20220025036A1 (en) | 2018-12-21 | 2022-01-27 | Novartis Ag | Use of il-1beta binding antibodies |
| KR20210107730A (ko) | 2018-12-21 | 2021-09-01 | 노파르티스 아게 | 골수 형성이상 증후군의 치료 또는 예방에서의 il-1 베타 항체의 용도 |
| CN113490528B (zh) | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN114502590A (zh) | 2019-09-18 | 2022-05-13 | 诺华股份有限公司 | Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法 |
| CN114786679A (zh) | 2019-10-21 | 2022-07-22 | 诺华股份有限公司 | 具有维奈托克和tim-3抑制剂的组合疗法 |
| BR112022007179A2 (pt) | 2019-10-21 | 2022-08-23 | Novartis Ag | Inibidores de tim-3 e usos dos mesmos |
| BR112022011902A2 (pt) | 2019-12-20 | 2022-09-06 | Novartis Ag | Terapias de combinação |
| BR112022012310A2 (pt) | 2020-01-17 | 2022-09-06 | Novartis Ag | Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica |
| KR102647829B1 (ko) * | 2020-04-22 | 2024-03-14 | 포항공과대학교 산학협력단 | 삼량체를 형성하는 코로나-19 바이러스 (COVID-19, Coronavirus Disease 2019)의 재조합 스파이크 단백질 및 식물에서의 상기 재조합 스파이크 단백질의 대량 생산 방법과 이를 기반으로하는 백신조성물 제조 방법 |
| JP2023529211A (ja) | 2020-06-11 | 2023-07-07 | ノバルティス アーゲー | Ｚｂｔｂ３２阻害剤及びその使用 |
| US20230235007A1 (en) * | 2020-06-15 | 2023-07-27 | Ming-Che Shih | Humanized ace2-fc fusion protein for treatment and prevention of sars-cov-2 infection |
| KR20230027056A (ko) | 2020-06-23 | 2023-02-27 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 |
| JP7819176B2 (ja) | 2020-08-03 | 2026-02-24 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| EP4204020A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
| EP4204021A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| CN113429488B (zh) * | 2021-07-14 | 2022-08-30 | 海正生物制药有限公司 | GITR/TGF-β双靶向融合蛋白及其用途 |
| WO2025191133A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Il-21 muteins, fusion proteins comprising the same and uses thereof |
| WO2025191136A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| DE19963859A1 (de) * | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| CN1809589A (zh) * | 2003-05-23 | 2006-07-26 | Wyeth公司 | Gitr配体和gitr配体相关分子和抗体及其应用 |
| US20080187954A1 (en) | 2004-03-10 | 2008-08-07 | Lonza Ltd. | Method For Producing Antibodies |
| DK1877090T3 (da) * | 2005-05-06 | 2014-04-14 | Providence Health System | Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf |
| US8591886B2 (en) * | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| TWI476001B (zh) * | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Ｆｃ融合蛋白及其用途 |
| WO2015116178A1 (en) * | 2014-01-31 | 2015-08-06 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector t cells |
| EP3148573A4 (en) | 2014-05-29 | 2017-11-15 | Medimmune, LLC | Ox40l fusion proteins and uses thereof |
-
2016
- 2016-08-11 JP JP2018506513A patent/JP2018522571A/ja active Pending
- 2016-08-11 AU AU2016306625A patent/AU2016306625A1/en not_active Abandoned
- 2016-08-11 KR KR1020187006894A patent/KR20180033588A/ko not_active Withdrawn
- 2016-08-11 HK HK18109492.4A patent/HK1250044A1/zh unknown
- 2016-08-11 HK HK18109489.9A patent/HK1250043A1/zh unknown
- 2016-08-11 BR BR112018002039A patent/BR112018002039A2/pt not_active Application Discontinuation
- 2016-08-11 EP EP16753881.8A patent/EP3334758A1/en not_active Withdrawn
- 2016-08-11 WO PCT/EP2016/069175 patent/WO2017025610A1/en not_active Ceased
- 2016-08-11 US US15/234,551 patent/US10428131B2/en not_active Expired - Fee Related
- 2016-08-11 MX MX2018001787A patent/MX2018001787A/es unknown
- 2016-08-11 TW TW105125874A patent/TW201718632A/zh unknown
- 2016-08-11 RU RU2018108236A patent/RU2018108236A/ru not_active Application Discontinuation
- 2016-08-11 CN CN201680045052.8A patent/CN108026158A/zh active Pending
- 2016-08-11 CA CA2994346A patent/CA2994346A1/en not_active Abandoned
-
2018
- 2018-01-23 IL IL257113A patent/IL257113A/en unknown
- 2018-02-08 CL CL2018000358A patent/CL2018000358A1/es unknown
- 2018-03-05 CO CONC2018/0002450A patent/CO2018002450A2/es unknown
- 2018-03-09 ZA ZA2018/01640A patent/ZA201801640B/en unknown
-
2019
- 2019-09-03 US US16/559,152 patent/US20200140510A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522571A5 (enExample) | ||
| RU2018108236A (ru) | Слитые белки на основе gitrl и пути их применения | |
| US12173082B2 (en) | Bispecific polypeptides against CD137 | |
| US10774150B2 (en) | Polypeptides | |
| US20220169751A1 (en) | Multimeric ox40 binding molecules and uses thereof | |
| JP7411627B2 (ja) | Ｉｌｔ４と結合する抗体 | |
| AU2015321546B2 (en) | Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof | |
| US20220106399A1 (en) | Multimeric cd40 binding molecules and uses thereof | |
| JP2021118754A (ja) | Ｃｄ３８に結合する抗体治療剤 | |
| CA3142738A1 (en) | Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function | |
| RU2016150096A (ru) | Белки слияния на основе ox40l и пути их применения | |
| JP7128819B2 (ja) | Ａｄａｍ９結合分子、およびその使用方法 | |
| KR20240095463A (ko) | 변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체 | |
| US20220073635A1 (en) | Novel polypeptides | |
| US11873348B2 (en) | Peptides | |
| Waight et al. | Harnessing co-stimulatory TNF receptors for cancer immunotherapy: current approaches and future opportunities | |
| EP4259645A1 (en) | Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function | |
| CA3220027A1 (en) | Bispecific fc fusion proteins with spd-1 and il-15 | |
| HK40128201A (en) | Adam9-binding molecules, and methods of use thereof | |
| HK40004686B (en) | Novel bispecific polypeptides against cd137 | |
| HK1241895B (en) | Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof | |
| HK1241895A1 (en) | Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof |